Loading...

MedXY News - breast cancer

MedXY AI/MedXY News/Tag: breast cancer

MedXY News

EnglishTag

breast cancer

68 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

GLP-1 Receptor Agonists May Outperform Bariatric Surgery for Breast Cancer Outcomes in Obese Postmenopausal Women

GLP-1 Receptor Agonists May Outperform Bariatric Surgery for Breast Cancer Outcomes in Obese Postmenopausal Women

In a large TriNetX study, GLP-1 receptor agonists were associated with better overall survival and lower locoregional recurrence than bariatric surgery alone in obese postmenopausal women with stage 0-III breast cancer.

Section: Diabetes & EndocrinologyJun 20, 2026

GLP-1 Receptor Agonists May Outperform Bariatric Surgery in Obese Postmenopausal Breast Cancer Patients, Study Suggests

GLP-1 Receptor Agonists May Outperform Bariatric Surgery in Obese Postmenopausal Breast Cancer Patients, Study Suggests

A large real-world study found GLP-1 receptor agonists were associated with better survival and lower locoregional recurrence than bariatric surgery in postmenopausal women with obesity and breast cancer.

Section: Hematology-OncologyJun 18, 2026

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial

Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in advanced hormone receptor-positive, ERBB2-negative breast cancer, with manageable safety and no clear quality-of-life loss.

Section: newsJun 10, 2026

Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM Study

Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM Study

This WISDOM Study analysis found that most women with breast cancer pathogenic variants would not have been flagged for high-risk screening by clinical or polygenic risk models alone, supporting population-based genetic testing.

Section: newsJun 10, 2026

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial

Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in hormone receptor-positive, ERBB2-negative advanced breast cancer with manageable toxicity and preserved quality of life.

Section: newsJun 3, 2026

Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial and Comparative Synthesis

Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial and Comparative Synthesis

This review synthesizes the BRIGHT-2 trial findings and meta-analytical data, confirming that bireociclib plus fulvestrant significantly improves progression-free survival in HR+/HER2- advanced breast cancer.

Section: Clinical UpdatesMay 27, 2026

Survival Outcomes After Neoadjuvant Chemotherapy in Node-Positive Hormone Receptor-Positive Breast Cancer”,

Survival Outcomes After Neoadjuvant Chemotherapy in Node-Positive Hormone Receptor-Positive Breast Cancer”,

A national database study found that neoadjuvant chemotherapy was linked to worse overall survival than upfront surgery in node-positive hormone receptor-positive, HER2-negative breast cancer, except in patients who achieved nodal complete

Section: General SurgeryMay 18, 2026

Quality of Breast Cancer Care and Patient Survival Show No Link to Hospital Safety-Net Burden

Quality of Breast Cancer Care and Patient Survival Show No Link to Hospital Safety-Net Burden

A major study reveals that safety-net hospitals—serving vulnerable Medicaid and uninsured patients—deliver breast cancer care and survival outcomes on par with other hospitals, challenging assumptions about quality disparities in resource-c

Section: newsMay 1, 2026

Tamoxifen and Uterine Disease Risk in Young Breast Cancer Survivors: Evidence from a Target Trial Emulation Study

Tamoxifen and Uterine Disease Risk in Young Breast Cancer Survivors: Evidence from a Target Trial Emulation Study

A large-scale cohort study of premenopausal women demonstrates that adjuvant tamoxifen significantly increases the risk of endometrial cancer, hyperplasia, and polyps, with risk correlating to treatment duration.

Section: Clinical UpdatesMar 13, 2026

Rethinking Frontline Standards: SONIA Trial Finds No Survival Benefit for First-Line CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer

Rethinking Frontline Standards: SONIA Trial Finds No Survival Benefit for First-Line CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer

The Phase 3 SONIA trial demonstrates that delaying CDK4/6 inhibitors to the second-line setting for advanced breast cancer yields comparable overall survival to first-line use, while significantly reducing treatment-related toxicities and h

Section: newsMar 12, 2026

The BMPR2 Nexus: How Breast Cancer Acts as a Second Hit for Pulmonary Hypertension

The BMPR2 Nexus: How Breast Cancer Acts as a Second Hit for Pulmonary Hypertension

Emerging evidence identifies a bidirectional link between breast cancer and pulmonary arterial hypertension (PAH) driven by BMPR2 signaling and IL-1β-mediated inflammation. This study suggests breast cancer may serve as a critical second hi

Section: CardiologyMar 2, 2026

Timing the Tactic: SONIA Trial Finds No Survival Advantage for First-Line vs. Second-Line CDK4/6 Inhibition in Advanced Breast Cancer

Timing the Tactic: SONIA Trial Finds No Survival Advantage for First-Line vs. Second-Line CDK4/6 Inhibition in Advanced Breast Cancer

The phase 3 SONIA trial demonstrates that initiating CDK4/6 inhibitors in the first-line setting does not improve overall survival compared to second-line use in HR-positive, ERBB2-negative advanced breast cancer, while significantly increa

Section: newsFeb 20, 2026

Environmental Cardiotoxicity: PM2.5 and Ozone Exposure Double the Risk of Cardiac Dysfunction in Breast Cancer Patients

Environmental Cardiotoxicity: PM2.5 and Ozone Exposure Double the Risk of Cardiac Dysfunction in Breast Cancer Patients

A prospective study reveals that PM2.5 and ozone exposure significantly exacerbate cardiac dysfunction and adverse remodeling in breast cancer patients receiving anthracyclines or trastuzumab, doubling the risk of clinical LVEF decline.

Section: CardiologyFeb 10, 2026

Mammography Screening and Mortality: A 40-Year European Population-Based Evaluation Shows Shift to Early-Stage Detection

Mammography Screening and Mortality: A 40-Year European Population-Based Evaluation Shows Shift to Early-Stage Detection

A massive 21-country study confirms that mammography screening has significantly shifted breast cancer detection toward earlier stages, contributing to a substantial decline in mortality across Europe, though treatment advances also play a

Section: newsJan 29, 2026

Liposomal Irinotecan Offers New Hope for HER2-Negative Breast Cancer Brain Metastases: Insights from the PHENOMENAL Study

Liposomal Irinotecan Offers New Hope for HER2-Negative Breast Cancer Brain Metastases: Insights from the PHENOMENAL Study

The PHENOMENAL phase 2 study reveals that liposomal irinotecan (nal-IRI) achieves a 22% intracranial objective response rate in patients with HER2-negative breast cancer and brain metastases, addressing a critical unmet need in neuro-oncolo

Section: newsJan 20, 2026

Machine Learning Accurately Predicts Distant Recurrence and Ribociclib Treatment Benefit in HR+/HER2- Early Breast Cancer

Machine Learning Accurately Predicts Distant Recurrence and Ribociclib Treatment Benefit in HR+/HER2- Early Breast Cancer

Researchers have developed a machine learning model using real-world and clinical trial data to predict distant recurrence risk and ribociclib’s therapeutic effect in HR+/HER2- early breast cancer, offering a potential tool for personalized

Section: newsJan 13, 2026

T-DXd Combinations Redefine Therapeutic Boundaries in HER2-Low Metastatic Breast Cancer: Key Findings from DESTINY-Breast08

T-DXd Combinations Redefine Therapeutic Boundaries in HER2-Low Metastatic Breast Cancer: Key Findings from DESTINY-Breast08

The DESTINY-Breast08 phase 1b study demonstrates that trastuzumab deruxtecan (T-DXd) combined with chemotherapy, AKT inhibitors, or endocrine therapy is manageable and clinically active in HER2-low metastatic breast cancer, offering new pat

Section: newsJan 13, 2026

Palbociclib, Trastuzumab, and Endocrine Therapy Significantly Extend Progression-Free Survival in PAM50 Luminal HER2-Positive Advanced Breast Cancer: Results from the SOLTI-1303 PATRICIA Trial

Palbociclib, Trastuzumab, and Endocrine Therapy Significantly Extend Progression-Free Survival in PAM50 Luminal HER2-Positive Advanced Breast Cancer: Results from the SOLTI-1303 PATRICIA Trial

The Phase II SOLTI-1303 PATRICIA trial (Cohort C) demonstrates that a triplet regimen of palbociclib, trastuzumab, and endocrine therapy significantly improves progression-free survival compared to physician’s choice treatments in pretreate

Section: newsJan 13, 2026

Neoadjuvant Abemaciclib plus Letrozole: A Potential Chemotherapy-Sparing Strategy in Select HR+/HER2- Breast Cancers?

Neoadjuvant Abemaciclib plus Letrozole: A Potential Chemotherapy-Sparing Strategy in Select HR+/HER2- Breast Cancers?

The CARABELA trial suggests that while neoadjuvant abemaciclib plus letrozole did not meet the threshold for similarity to chemotherapy in highly proliferative HR+/HER2- breast cancer, it remains a viable alternative for patients with lower

Section: newsJan 12, 2026

Genomic Evolution of Breast Cancer: How Acquired Gene Fusions Drive Metastatic Progression and Treatment Resistance

Genomic Evolution of Breast Cancer: How Acquired Gene Fusions Drive Metastatic Progression and Treatment Resistance

A multi-omics analysis from the AURORA program reveals that metastatic breast cancer carries a significantly higher burden of gene fusions than primary tumors. Acquired fusions, particularly involving ESR1, are linked to genomic instability

Section: newsJan 12, 2026

Prev 1 2 3 4 Next